首页>
外国专利>
a method of treating egfr cancer targeted to erlotinib or gefitinib resistant or using a pharmaceutically acceptable salt in an individual
a method of treating egfr cancer targeted to erlotinib or gefitinib resistant or using a pharmaceutically acceptable salt in an individual
展开▼
机译:在个体中治疗针对埃罗替尼或吉非替尼耐药或使用可药用盐的egfr癌症的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.
展开▼